2024
Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies
Weitzen M, Shahbazy M, Kapoor S, Caron E. Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. Frontiers In Immunology 2024, 15: 1442783. PMID: 39301027, PMCID: PMC11410602, DOI: 10.3389/fimmu.2024.1442783.Peer-Reviewed Original ResearchMass spectrometryHLA-EHLA moleculesT-cell-directed immunotherapyCD8+ T cellsNovel cell surface antigensNon-classical HLA-EHLA-E moleculesCell surface antigensPeptides to CD8T cellsMRNA vaccinesTherapeutic efficacySurface antigensImmunotherapyMoleculesSpectrometryTherapeutic targetImmunopeptidomePathogen-derivedCD8Peptide repertoirePeptide fragmentsHLAMinimal polymorphism
2021
The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype-dependent manner
Hamelin D, Fournelle D, Grenier J, Schockaert J, Kovalchik K, Kubiniok P, Mostefai F, Duquette J, Saab F, Sirois I, Smith M, Pattijn S, Soudeyns H, Decaluwe H, Hussin J, Caron E. The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype-dependent manner. Cell Systems 2021, 13: 143-157.e3. PMID: 34637888, PMCID: PMC8492600, DOI: 10.1016/j.cels.2021.09.013.Peer-Reviewed Original ResearchConceptsSARS-CoV-2SARS-CoV-2 TSARS-CoV-2 variantsHLA-B allelesMutational landscapeFirst yearCell immunityCell immunosurveillanceCell epitopesMass vaccinationDelta variantCell targetsRNA levelsImmunodominant onesMutation typeEpitopesPrevalent mutantsPopulation levelCD8PandemicImmunosurveillanceVaccinationHLAYearsImmunity
2018
A tissue-based draft map of the murine MHC class I immunopeptidome
Schuster H, Shao W, Weiss T, Pedrioli P, Roth P, Weller M, Campbell D, Deutsch E, Moritz R, Planz O, Rammensee H, Aebersold R, Caron E. A tissue-based draft map of the murine MHC class I immunopeptidome. Scientific Data 2018, 5: 180157. PMID: 30084848, PMCID: PMC6080492, DOI: 10.1038/sdata.2018.157.Peer-Reviewed Original ResearchConceptsMHC class IClass IMurine MHC class IPotential tumor-associated antigenMajor histocompatibility complex class IHistocompatibility complex class ITumor-associated antigensComplex class IC57BL/6 miceT cellsTranslational immunologyCancer modelImmune systemNormal tissuesMS injectionMost tissuesTissueInitial qualitative dataTotal numberPeptidesCD8AtlasAntigenMice
2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515: 577-581. PMID: 25428507, PMCID: PMC4279952, DOI: 10.1038/nature13988.Peer-Reviewed Original Research